Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2025 May 8;51(3):742-753.
doi: 10.1093/schbul/sbae080.

Cognitive Behavioral Psychotherapy as an Add-on in Comprehensive Outpatient Care of Non-affective Psychoses: A Multicenter Randomized-Controlled Effectiveness Trial in a Naturalistic Setting

Affiliations
Randomized Controlled Trial

Cognitive Behavioral Psychotherapy as an Add-on in Comprehensive Outpatient Care of Non-affective Psychoses: A Multicenter Randomized-Controlled Effectiveness Trial in a Naturalistic Setting

Carolin Steuwe et al. Schizophr Bull. .

Abstract

Background and hypothesis: Non-affective psychoses (NAP) are associated with severe consequences with regard to social functioning, physical health, employment, and suicidality. Treatment guidelines recommend cognitive behavioral therapy for psychosis (CBTp) as an effective additional treatment strategy to psychopharmacology. We hypothesized that outpatient CBTp has an add-on effect in individuals with NAP who already receive comprehensive outpatient care (COC) in Germany.

Study design: In a randomized-controlled effectiveness trial, 6 months of COC + CBTp were compared to COC. The primary outcomes were change of symptom severity as assessed by the Positive and Negative Symptom Scale (pre-/post-treatment and 6-month follow-up). Mixed linear models and effect sizes were used to compare changes across treatment groups. Additionally, the number of readmissions was compared.

Study results: N = 130 individuals with chronic NAP were recruited (COC + CBTp: n = 64, COC: n = 66). COC + CBTp participants significantly improved more regarding positive symptom severity (estimated mean difference at follow-up: -2.33, 95% CI: -4.04 to -0.61, P = .0083, d = 0.32) and general psychopathology (estimated mean difference at follow-up: -4.55, 95% CI: -7.30 to -1.81, P = .0013, d = 0.44) than the COC group. In both groups, negative symptom severity did not change significantly over time nor did groups differ regarding readmissions.

Conclusion: The results underline an add-on benefit of CBTp in chronically ill individuals with NAP. Superiority of CBTp was demonstrated in comparison with high-quality comprehensive care and may also be true in different comprehensive care settings.

Clinical trials registration: DRKS00015627.

Keywords: RCT; clinical trial; schizophrenia; treatment effects.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Patient flow. CBTp = cognitive behavioral therapy for psychosis, COC = comprehensive outpatient care.
Fig. 2.
Fig. 2.
Boxplots of the primary outcome of PANSS-scores for positive (A) and negative (B) symptoms as well as general psychopathology (C) for each time point and treatment arm. CBTp = cognitive behavioral therapy for psychosis; COC = comprehensive outpatient care; PANSS = Positive and Negative Syndrome Scale. *P ≤ .05, ****P ≤ .0001 (Tukey-corrected).

Similar articles

Cited by

References

    1. Jauhar S, Johnstone M, McKenna PJ.. Schizophrenia. Lancet (London, England). 2022;399(10323):473–486. - PubMed
    1. Hjorthøj C, Stürup AE, McGrath JJ, Nordentoft M.. Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis. Lancet Psychiatry. 2017;4(4):295–301. - PubMed
    1. Jääskeläinen E, Juola P, Hirvonen N, et al. A systematic review and meta-analysis of recovery in schizophrenia. Schizophr Bull. 2013;39(6):1296–1306. - PMC - PubMed
    1. Ruggeri M, Leese M, Thornicroft G, Bisoffi G, Tansella M.. Definition and prevalence of severe and persistent mental illness. Br J Psychiatry. 2000;177(2):149–155. - PubMed
    1. DGPPN. S3-Leitlinie Schizophrenie. 2019. https://www.awmf.org/leitlinien/detail/ll/038-009.html. Date accessed January 23, 2023.

Publication types